adaura: osimertinib post-tumor resection in nsclc
Published 4 years ago • 329 plays • Length 8:06Download video MP4
Download video MP3
Similar videos
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
1:42
adaura: the benefit of adjuvant osimertinib
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
4:24
reflections on the adaura study
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
5:03
adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
-
2:06
adaura trial: osimertinib for early stage egfr nsclc - 2022 program: targeted therapies forum
-
5:54
key points from the adaura trial: osimertinib - targeted therapies in lung cancer 2023
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
0:58
adaura study demonstrates promising efficacy for osimertinib in egfr-mutant nsclc
-
3:52
is adjuvant chemotherapy in egfr mutated nsclc still required?
-
5:12
adaura trial: tagrisso & resectable egfr - leading developments & current questions in lung cancer
-
16:41
asco lung cancer roundtable - trial updates in nsclc - adaura trial and post surgery egfr mutation
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
0:50
targeted option for non-small cell lung cancer #2023 #oncology #lungcancer